YR0097
Human EGFR Monoclonal Antibody
Size
£355.00
- SKU:
- YR0097
- Additional Names:
- ERBB|ERBB1|ERRP|HER1|mENA|NISBD2|PIG61
- Application:
- ELISA, FuncS, Neutralisation
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- Abclonal
- Immunogen:
- Human EGFR
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Uniprot:
- P00533
- Synonyms:
- avian erythroblastic leukemia viral (v-erb-b) oncogene homolog;cell growth inhibiting protein 40;cell proliferation-inducing protein 61;epidermal growth factor receptor;epidermal growth factor receptor tyrosine kinase domain;erb-b2 receptor tyrosine kinase 1;ERBB;ERBB1;ERRP;HER1;mENA;NISBD2;PIG61;proto-oncogene c-ErbB-1;receptor tyrosine-protein kinase erbB-1
- Extra Details:
- Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 K Kappa-chain.Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.
- Shipping Conditions:
- Blue Ice